 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 05, 2022 GLOBE NEWSWIRE -- Molecular Partners AG SIX: MOLN; NASDAQ: MOLN, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in several upcoming healthcare investor events in January, 2022. 